Squarepoint
UNCY icon

Squarepoint’s Unicycive Therapeutics UNCY Stock Holding History

Squarepoint’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,305
Closed -$319K – 5005
2025
Q4 		$319K Sell
55,305
-62,022
-53% -$331K ﹤0.01% 3555
2025
Q3 		$512K Buy
+117,327
New +$511K ﹤0.01% 3216
2023
Q2 		– Sell
-1,146
Closed -$24.1K – 4035
2023
Q1 		$24.1K Buy
+1,146
New +$11.4K ﹤0.01% 3117

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's UNCY Position: Q1 2026 in Review

Squarepoint sold out of Unicycive Therapeutics (UNCY) in Q1 2026, closing a stake of 55,305 shares — an estimated $319K sold.

Squarepoint first reported a position in UNCY in Q1 2023 and held it in 3 quarters. The position peaked at $512K in Q3 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Squarepoint reported no remaining Unicycive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 55,305 Unicycive Therapeutics shares in Q1 2026, an estimated $319K.
  • Squarepoint first reported a position in Unicycive Therapeutics in Q1 2023 and held it in 3 quarters.
  • Squarepoint's Unicycive Therapeutics position peaked at $512K in Q3 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.